Chen Q, et al. - In this single-center retrospective study involving 39 infants (42 eyes) aged ≤3 months, researchers tested the effectiveness and safety of intra-arterial chemotherapy (IAC) for the primary or secondary treatment of infants diagnosed with advanced retinoblastoma before 3 months of age. Participants in the study were infants who were diagnosed and treated for advanced intraocular retinoblastoma from June 2012 to February 2017. Investigators found that in infants aged < 3 months, IAC whether primary or secondary is effective and fairly safe for the management of advanced retinoblastoma. Nevertheless, adverse injection-related events and visual results can not be overlooked and need further investigation. This therapy should be used with caution in very young infants until the accurate advantages and hazards of IAC are recognized.